Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 4 | uM | 12178.145 | 0.7788 | 0.3300 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 20 | uM | 12178.145 | 0.6221 | -0.0784 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 100 | uM | 12178.145 | 0.6174 | -0.0897 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.0000853 | uM | 12291.17 | 0.8911 | 0.6269 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.000427 | uM | 12291.17 | 0.8892 | 0.6208 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.00213 | uM | 12291.17 | 1.0196 | 1.0706 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.0107 | uM | 12291.17 | 0.9076 | 0.6812 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.0533 | uM | 12291.17 | 0.9369 | 0.7796 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.267 | uM | 12291.17 | 0.9091 | 0.6864 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 1.33 | uM | 12291.17 | 0.7396 | 0.1655 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 6.67 | uM | 12291.17 | 0.4573 | -0.5072 | 0.5585 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 33.3 | uM | 12291.17 | 0.4215 | -0.5742 | 0.5585 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 10696.145 | 0.9677 | 0.8114 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 10696.145 | 0.9415 | 0.6673 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 10696.145 | 0.9381 | 0.6495 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 10696.145 | 0.9806 | 0.8852 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 10696.145 | 1.0608 | 1.3898 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 10696.145 | 0.9904 | 0.9425 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 4 | uM | 10696.145 | 0.8767 | 0.3448 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 20 | uM | 10696.145 | 0.6488 | -0.4573 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 100 | uM | 10696.145 | 0.5711 | -0.6307 | 0.3316 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 11855.145 | 0.9304 | 0.7348 | 0.5070 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 11855.145 | 0.8777 | 0.5461 | 0.5070 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 11855.145 | 0.9007 | 0.6273 | 0.5070 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 11855.145 | 0.9338 | 0.7473 | 0.5070 |